CU SOM Faculty Awarded NCCN Clinical Trial GrantApr 23, 2021
The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) has announced “Oral Decitabine/Cedazuridine (INQOVI) in Combination with Nivolumab as a Strategy to Enhance the Efficacy of Immune Checkpoint Blockade in Unresectable or Metastatic Mucosal Melanoma" as one of three selected projects to study oral decitabine (35 mg) and cedazuridine (100 mg).
This trial spearheaded by Dr. Martin McCarter (Department of Surgery), Dr. Theresa Medina (Division of Medical Oncology), and Dr. Kasey Couts (Division of Medical Oncology), is a first of its kind in that it will focus specifically on patients with mucosal melanoma. The first trial to be launched since the establishment of the CU Center for Rare Melanomas, this project is based on Dr. Couts' preclinical research and will combine an oral tablet form of decitabine, a hypomethylating agent, with Nivolumab as an epigenetic priming strategy to improve anti-PD1 immunotherapy efficacy specifically in patients with advanced melanoma of mucosal origin.
Research funding will be provided by a grant from Taiho Oncology, who will also supply the decitabine and cedazuridine tablet.
“Congratulations to all of the selected investigators,” said Wui-Jin Koh, MD, Chief Medical Officer, NCCN. “We look forward to their work advancing our understanding of this medication combination. The potential for oral medication in place of intravenous delivery is particularly worthy of exploration, as this may provide better options for outpatient therapy with reduced office visits, which in turn improves access to care and helps underserved patient populations.
“Taiho Oncology is pleased to continue our collaboration with the National Comprehensive Cancer Network to help broaden the understanding of oral decitabine and cedazuridine for patients with solid tumors and hematologic malignancies,” said Terri L. Washington, DNP, RN, Vice President, Scientific Partnerships and Medical Affairs Operations, Taiho Oncology, Inc. “These grants will help advance critical research and represent a step forward in exploring the full potential of oral decitabine and cedazuridine for patients to help improve outcomes.”
The NCCN ORP fosters innovation and knowledge discovery that improves the lives of people with cancer and supports preclinical, translational, clinical research and quality improvement projects in oncology at NCCN Member Institutions. In an effort to improve collaboration in cancer research, the NCCN ORP also maintains a shared resources website and an informed consent database. For more information, visit NCCN.org/orp.